BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 20373143)

  • 1. Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting.
    Lindner M; Hoffmann GF; Matern D
    J Inherit Metab Dis; 2010 Oct; 33(5):521-6. PubMed ID: 20373143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening.
    Spiekerkoetter U
    J Inherit Metab Dis; 2010 Oct; 33(5):527-32. PubMed ID: 20449660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and biochemical monitoring of patients with fatty acid oxidation disorders.
    Lund AM; Skovby F; Vestergaard H; Christensen M; Christensen E
    J Inherit Metab Dis; 2010 Oct; 33(5):495-500. PubMed ID: 20066495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical aspects of short-chain acyl-CoA dehydrogenase deficiency.
    van Maldegem BT; Wanders RJ; Wijburg FA
    J Inherit Metab Dis; 2010 Oct; 33(5):507-11. PubMed ID: 20429031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatty acid oxidation disorders: outcome and long-term prognosis.
    Wilcken B
    J Inherit Metab Dis; 2010 Oct; 33(5):501-6. PubMed ID: 20049534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and biochemical outcome of patients with very long-chain acyl-CoA dehydrogenase deficiency.
    Rovelli V; Manzoni F; Viau K; Pasquali M; Longo N
    Mol Genet Metab; 2019 May; 127(1):64-73. PubMed ID: 31031081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of newborn screening for fatty acid oxidation disorders on neurological outcome: A Belgian retrospective and multicentric study.
    Everard E; Laeremans H; Boemer F; Marie S; Vincent MF; Dewulf JP; Debray FG; De Laet C; Nassogne MC
    Eur J Paediatr Neurol; 2024 Mar; 49():60-65. PubMed ID: 38377647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and genetic characteristics of patients with fatty acid oxidation disorders identified by newborn screening.
    Kang E; Kim YM; Kang M; Heo SH; Kim GH; Choi IH; Choi JH; Yoo HW; Lee BH
    BMC Pediatr; 2018 Mar; 18(1):103. PubMed ID: 29519241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infants suspected to have very-long chain acyl-CoA dehydrogenase deficiency from newborn screening.
    Merritt JL; Vedal S; Abdenur JE; Au SM; Barshop BA; Feuchtbaum L; Harding CO; Hermerath C; Lorey F; Sesser DE; Thompson JD; Yu A
    Mol Genet Metab; 2014 Apr; 111(4):484-92. PubMed ID: 24503138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent ACADVL molecular findings in individuals with a positive newborn screen for very long chain acyl-coA dehydrogenase (VLCAD) deficiency in the United States.
    Miller MJ; Burrage LC; Gibson JB; Strenk ME; Lose EJ; Bick DP; Elsea SH; Sutton VR; Sun Q; Graham BH; Craigen WJ; Zhang VW; Wong LJ
    Mol Genet Metab; 2015 Nov; 116(3):139-45. PubMed ID: 26385305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic characteristics and follow-up of patients with fatty acid β-oxidation disorders through expanded newborn screening in a Northern Chinese population.
    Wang S; Leng J; Diao C; Wang Y; Zheng R
    J Pediatr Endocrinol Metab; 2020 May; 33(6):683-690. PubMed ID: 32447334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.
    Yamada K; Taketani T
    J Hum Genet; 2019 Feb; 64(2):73-85. PubMed ID: 30401918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of newborn screening for very-long-chain acyl-CoA dehydrogenase deficiency on genetic, enzymatic, and clinical outcomes.
    Bleeker JC; Kok IL; Ferdinandusse S; van der Pol WL; Cuppen I; Bosch AM; Langeveld M; Derks TGJ; Williams M; de Vries M; Mulder MF; Gozalbo ER; de Sain-van der Velden MGM; Rennings AJ; Schielen PJCI; Dekkers E; Houtkooper RH; Waterham HR; Pras-Raves ML; Wanders RJA; van Hasselt PM; Schoenmakers M; Wijburg FA; Visser G
    J Inherit Metab Dis; 2019 May; 42(3):414-423. PubMed ID: 30761551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diversity in the incidence and spectrum of organic acidemias, fatty acid oxidation disorders, and amino acid disorders in Asian countries: Selective screening vs. expanded newborn screening.
    Shibata N; Hasegawa Y; Yamada K; Kobayashi H; Purevsuren J; Yang Y; Dung VC; Khanh NN; Verma IC; Bijarnia-Mahay S; Lee DH; Niu DM; Hoffmann GF; Shigematsu Y; Fukao T; Fukuda S; Taketani T; Yamaguchi S
    Mol Genet Metab Rep; 2018 Sep; 16():5-10. PubMed ID: 29946514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial fatty acid oxidation disorders: pathophysiological studies in mouse models.
    Spiekerkoetter U; Wood PA
    J Inherit Metab Dis; 2010 Oct; 33(5):539-46. PubMed ID: 20532823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical manifestation of MCAD deficiency: challenges towards adulthood in the screened population.
    Schatz UA; Ensenauer R
    J Inherit Metab Dis; 2010 Oct; 33(5):513-20. PubMed ID: 20532824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation analysis in mitochondrial fatty acid oxidation defects: Exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship.
    Gregersen N; Andresen BS; Corydon MJ; Corydon TJ; Olsen RK; Bolund L; Bross P
    Hum Mutat; 2001 Sep; 18(3):169-89. PubMed ID: 11524729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-invasive test using palmitate in patients with suspected fatty acid oxidation defects: disease-specific acylcarnitine patterns can help to establish the diagnosis.
    Janzen N; Hofmann AD; Schmidt G; Das AM; Illsinger S
    Orphanet J Rare Dis; 2017 Dec; 12(1):187. PubMed ID: 29268767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Screening for fatty acid oxidation disorders of newborns in Zhejiang province:prevalence, outcome and follow-up].
    Zheng J; Zhang Y; Hong F; Yang J; Tong F; Mao H; Huang X; Zhou X; Yang R; Zhao Z; Huang X
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2017 May; 46(3):248-255. PubMed ID: 29039165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for newborn fatty acid oxidation disorders in Chongqing and the follow-up of confirmed children.
    Chen M; Yin Y; Liu H; Peng Y; Ye L; Luo Q; Miao J
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 51(3):290-297. PubMed ID: 36207828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.